Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease
Neurodegenerative Disorder Alzheimer's Disease (AD)
For the latest version of this information please go to www.forpatients.roche.com